Pharvaris (NASDAQ:PHVS) Insider Sells 10,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 10,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $29.92, for a total value of $299,200.00. Following the completion of the sale, the insider directly owned 45,111 shares of the company’s stock, valued at approximately $1,349,721.12. This trade represents a 18.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Pharvaris Stock Performance

Shares of PHVS stock traded up $0.14 on Tuesday, reaching $28.95. 301,435 shares of the company’s stock traded hands, compared to its average volume of 226,184. The company has a market capitalization of $1.89 billion, a P/E ratio of -9.10 and a beta of -2.34. Pharvaris N.V. has a 12-month low of $15.46 and a 12-month high of $33.33. The business’s 50 day moving average price is $28.20 and its two-hundred day moving average price is $26.63.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. Research analysts predict that Pharvaris N.V. will post -3.35 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PHVS. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. UBS Group set a $74.00 target price on shares of Pharvaris in a research report on Wednesday, May 13th. Wedbush increased their target price on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Wall Street Zen upgraded shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.18.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors have recently modified their holdings of the company. General Atlantic L.P. boosted its holdings in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC raised its holdings in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC lifted its position in Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after acquiring an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. boosted its holdings in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after acquiring an additional 425,000 shares during the period. Finally, Commodore Capital LP boosted its holdings in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
• Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.